公开(公告)号：US10556256B2

公开(公告)日：2020-02-11

申请号：US15314187

申请日：2015-05-27

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Naoyuki Murata ,  Jiichi Arai

IPC: B82Y30/00 ,  B08B3/10 ,  A61K47/02 ,  A61K47/20 ,  A61K33/00 ,  C02F1/68 ,  A61K47/34 ,  A61K47/32 ,  A61K9/00 ,  A61L2/02 ,  A61L9/012 ,  C02F1/24

Abstract: A novel technique is provided for preserving a liquid pharmaceutical preparation safely and stably. The nano-bubble water of the present invention, which is produced in the presence of a surfactant, a hydrophilic resin and/or an electrolyte and contains not less than 2.0×108 bubbles/mL of nano-bubbles, shows a superior antibacterial action, and can be used as a base of a liquid pharmaceutical preparation showing safe and stable preservation property.

公开(公告)号：US12178981B2

公开(公告)日：2024-12-31

申请号：US16958388

申请日：2018-12-26

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Naoyuki Murata ,  Shigeo Yanai

IPC: A61M37/00 ,  A61K41/00 ,  A61K49/22

Abstract: The present disclosure provides a safer novel opening system with highly broad utility for a blood-brain barrier (BBB), the opening system containing a combination of (1) nano-bubble water or nano-bubble aqueous solution containing nano-bubbles having an average diameter of not more than 200 nm, and (2) an ultrasound generating apparatus; a method for opening a BBB, including using the nano-bubble water or nano-bubble aqueous solution, and an ultrasound; and a method for increasing BBB permeability of a drug, including using the nano-bubble water or nano-bubble aqueous solution, and an ultrasound.

公开(公告)号：US09364438B2

公开(公告)日：2016-06-14

申请号：US14430956

申请日：2013-09-25

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Naoyuki Murata ,  Shigeo Yanai

IPC: A61K9/14 ,  A61K31/18 ,  A61K31/24 ,  A61K9/16

CPC classification number: A61K9/1688 ,  A61K9/14 ,  A61K31/18 ,  A61K31/24

Abstract: A method of producing crystal of a poorly water-soluble pharmaceutical compound, including mixing a solution of a poorly water-soluble pharmaceutical compound in a good solvent and nanobubble water or an aqueous nanobubble solution to precipitate crystal of the poorly water-soluble pharmaceutical compound. The crystal of a poorly water-soluble pharmaceutical compound obtained by the method is microparticulate and has more uniform particle size distribution, and is superior in the absorbability and sustainability.

Abstract translation: 一种生产水溶性差的药物化合物的方法，包括将难溶于水的药物化合物的溶液与纳米气泡水溶液或纳米气泡水溶液混合，使难溶于水的药物化合物的晶体析出。 通过该方法得到的水溶性差的药物的结晶为微粒状，粒径分布更均匀，吸收性和可持续性优异。

公开(公告)号：US20150250728A1

公开(公告)日：2015-09-10

申请号：US14430956

申请日：2013-09-25

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Naoyuki Murata ,  Shigeo Yanai

IPC: A61K9/16 ,  A61K31/24

CPC classification number: A61K9/1688 ,  A61K9/14 ,  A61K31/18 ,  A61K31/24

Abstract: A method of producing crystal of a poorly water-soluble pharmaceutical compound, including mixing a solution of a poorly water-soluble pharmaceutical compound in a good solvent and nanobubble water or an aqueous nanobubble solution to precipitate crystal of the poorly water-soluble pharmaceutical compound. The crystal of a poorly water-soluble pharmaceutical compound obtained by the method is microparticulate and has more uniform particle size distribution, and is superior in the absorbability and sustainability.

Abstract translation: 一种生产水溶性差的药物化合物的方法，包括将难溶于水的药物化合物的溶液与纳米气泡水溶液或纳米气泡水溶液混合，使难溶于水的药物化合物的晶体析出。 通过该方法得到的水溶性差的药物的结晶为微粒状，粒径分布更均匀，吸收性和可持续性优异。